Introduction
Recent advancements in biological therapies have initiated a shift from the traditional 'one-size fits all' approach towards personalized medicinal strategies. Advanced Therapy Medicinal Products (ATMPs) are at the forefront of this new tendency. ATMP is the umbrella term for three drug product classes: Somatic cell therapies, gene therapeutics and tissue engineered products as well as a combination of these technologies with a medicinal product. All ATMP classes contain either living cells or viral vectors and are therefore characterized by a high degree of complexity. Cells are usually derived from a patient or an allogeneic donor, processed in the laboratory (e.g. expanded in vitro or genetically engineered) and (re-) administered to the patient in a hospital. Gene therapy is designed to introduce genetic material into living cells to compensate for abnormal genes or express a beneficial protein.
On 30 December 2008, the Regulation 1394/2007 amending Directive 2001/83/EC on Advanced Therapy Medicinal Products entered into force and the first European Union wide regulatory framework for ATMPs was established [1] . This framework changed the code of regulatory practices, as a central marketing authorisation issued by the European Medicinal Agency (EMA) was required from now on. Previously, registration was not required for autologous products and pivotal clinical trials were not mandatory [2] . Not all ATMPs target high prevalence indications. In case of orphan diseases with a prevalence not more than 5 in 10.000, the ATMP regulation poses complex challenges to the design of clinical trials [2, 3] .
In recognition of the small scale and developmental nature of some intra-hospital ATMP applications, the regulation 2001/83/EC includes a 'Hospital exemption' for products not intended to be marketed. ATMPs applied via Hospital exemption must be prepared on a non-routine basis in a non-industrial manner and used as a custom made product for an individual patient [4] . However, the meanings of 'non-routine basis', 'industrial manner' and 'custom made' are not specified by the regulation and interpretations differ among different European countries [5] . ATMPs without a centralized European marketing authorisation can therefore still be approved in individual member states.
The aim of the presented study is to give an overview on ATMPs currently available within the European Union either via a centralized marketing authorisation or via national approval in an individual member state. ATMPs withdrawn from the market will be identified and the reasons for withdrawal analysed. Additionally, a forecast on innovative ATMPs in the process of EMA approval as well as products in phase III and IV clinical trial will be presented.
Methods

Search strategy
A systematic database review was conducted to identify published studies from Ovid MEDLINE, Ovid EMBASE, the Cochrane Library and clinicaltrials.gov. Details on clinical trials were also collected from clinicaltrialsregister.eu. Additional information was gathered from the homepage of the European Medicines Agency (www.ema.europa.eu) as well as from the webpages of the national competent authorities. A manual search for grey literature was performed following pre-defined search terms. Additionally, the national competent authorities were contacted to obtain information on ATMPs licensed via Hospital exemption.
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Eligibility criteria
Publications targeting an ATMP approved by the EMA or in the process of an EMA approval as well as manuscripts targeting phase III and IV ATMP clinical trials were included in this review. Additionally, publications on ATMPs administered to patients via Hospital exemption were included. Products were excluded from evaluation if their ATMP status could not be clearly assessed, e.g. in case of cancer immunotherapeutics which had neither been submitted to the EMAs Committee for Advanced Therapies (CAT) for classification nor declared as ATMP in the reference literature. Further inclusion and exclusion criteria are detailed in Table 1 .
Data extraction
The following clinical trial data were extracted using MS Excel 2011: ATMP, registration number, manufacturer, indication, clinical trial status and eventual marketing authorisation status. Duplicates with the same registration number were removed as well as all pre-clinical, phase I and II studies, observational studies, studies performed outside the European Union and studies with an unclear phase assignment. Clinical trials not targeting an ATMP as well as generic conference abstracts not containing concrete clinical data were also excluded.
Results
Search results
The literature search yielded 2.613 publications. After removal of duplicates, pre-clinical, phase I and II studies, observational studies and studies with an unclear phase assignment 502 full text records were considered for evaluation. 91 did not meet the inclusion criteria (mostly studies performed outside of the European Union). Finally, we identified 412 studies for investigation.
The clinical trials database search yielded 1.946 entries in European Union member states. In 1.516 trials, the interventional drug was not an ATMP. 430 clinical trials were included in the evaluation. After manual removal of duplicates resulting from multi-centre international clinical trials, 160 phase III and IV studies were reviewed. 20 did not meet the inclusion criteria (either erroneously reported as phase III in the database or not Figure 1 . The substance was able to prolong median patient survival by 4,1 months. After a 3 years follow up, the proportion of patients alive in the vaccine group was 50% higher than in the control group [7] . Provenge® was approved by the EMA in 2012 and priced $93.000 per treatment [8] .
ATMPs with a valid central European marketing authorisation
Supply chain conditions were highly complex: Within a cooled, insulated container, shelf live was only 18 hours [9] . Due to the high price, a highly complex way of administration and reimbursement issues the product failed on the market and the manufacturer filed bankruptcy in 2015 [8] .
MACI was on the market since 1998 in individual EU countries according to national procedures [10] . In 2013, the product was granted a central marketing authorisation for repair of cartilage defects in the knee joint. Due to commercial reasons, the company closed the European manufacturing site in 2014. Consequently, the marketing authorisation was suspended and expired during the suspension period [11] .
Glybera® was an adenoassociated viral vector for treatment of lipoprotein lipase deficiency (LLD), a ultra-rare disease affecting only 1 in a million people [12] . The product was authorised under exceptional circumstances based on data received from 3 phase III trials enrolling a total of 27 patients [13] . Despite the clinical success, the product was a commercial failure. Four and a half years after making history for obtaining EMA approval as the first gene therapy in a regulated market, the manufacturer did not renew marketing approval and Glybera® was withdrawn in October 2017. In fact, only one patient had been treated with the commercial form of the LLD therapy, which was priced at 1,1 Million € [14] .
ChondroCelect® (characterized, viable autologous cartilage cells expanded ex vivo expressing specific marker proteins) was approved in October 2009. The pivotal clinical trial demonstrated a superior structural cartilage repair when compared to standard Microfracture treatment [15] . Despite positive results, the product was withdrawn from the market in 2016 due to a lack of reimbursement in key European countries [9] .
ATMPs in the process of EMA approval (planned launch before 2020) Until 2020, 6 new ATMPs shall be launched on the European market. Developing companies, indications and clinical/ regulatory status are summarized in Table 4 . The Committee for Medicinal products for Human Use (CHMP) has already recommended the granting of a marketing authorisation for Luxturna™, a gene therapy for treatment of inherited retinal dystrophy [16] . LentiGlobin™ is a potential gene therapy for correction of transfusion dependant thalassemia and sickle cell disease. Published Table 3 . ATMPs with a valid central European marketing authorisation by August 2018.
Holoclar® Holoclar® was the first stem cell based ATMP approved by the European Union. The product is based on ex vivo expanded autologous human corneal epithelial cells [10] . The cells are isolated from a limbus tissue biopsy, expanded in vitro and cryopreserved for alignment with the patient´s medical care. After thawing, the cells are seeded onto a fibrin matrix for transplantation [11] .
Imlygic®
Imlygic®was the first oncologic gene therapy reaching EMA approval. The product is based on a genetically modified oncolytic virus replicating within the tumoral tissue to produce granulocyte-macrophage colony stimulating factor (GM-CSF). Intratumoral application leads to tumor cell lysis and the release of tumor-derived antigens, which -in combination with GM-CFS -amplify the body´s antitumoral immune response [12] . Strimvelis® Strimvelis® is designed to treat severe combined immunodeficiency (SCID) due to Adenosin desaminase deficiency (ADA-SCID) in patients who cannot be treated with a bone marrow transplant due to lack of a suitable donor [13] . The product is based on autologous CD 34+ cells transduced with a retroviral vector encoding for the human ADA cDNA sequence [10] . Zalmoxis® Zalmoxis® is a patient specific immunogenic therapy serving as adjunctive treatment in haplo-identical haematopoietic stem cell transplantation in patients with leukaemia and high-risk haematological malignancies [14] . Data from 45 patients treated with Zalmoxis showed a survival rate of 49% after one year. Survival in the control group was 37% [15] . Spherox® Spherox® are spheroids of human autologous matrix-associated chondrocytes for treatment of cartilage defects in the knee joint [16] . Data of 30 patients after an average follow-up of 3 years demonstrate a significant increase in quality of life, pain reduction and an improvement of joint function [17] . Alofisel® Alofisel® consists of adipose tissue derived allogeneic mesenchymal stem cells for injection into the perianal fistula tract in Cohn's disease [18] . Local application of Alofisel® in conjunction with surgical preparation of the fistula tract has been shown to induce and maintain fistula closure, but a high placebo effect due to background therapies was noted in the phase III clinical trial [19] . Kymriah® Kymriah® (CTL019/tisagenlecleucel) is intended for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia and for adult patients with diffuse large B-cell lymphoma who are ineligible for stem cell transplantation. In paediatric patients, an overall remission rate of 81% was achieved in the ELIANA trial [20] . Adult patients with diffuse large B-cell lymphoma achieved an overall response rate of 52% [21] . Treatment related adverse events occurred in 95% of the patients, mostly as cytokine release syndrome. Yescarta® Yescarta® (axicabtagene ciloleucel) is a chimeric antigen receptor T-cell therapy to treat aggressive non-Hodgkin´s lymphomas. In patients with large B-cell lymphoma, primary mediastinal B-cell lymphoma and transformed follicular lymphoma, the overall response rate was 71%. Complete remission was achieved in 57% (5/7) of the patients [22] . Adverse events include anaemia, neutropenia and decreased white blood cell count. Grade III or higher cytokine release syndrome is observed in 13% and neurologic events in 28% of the patients [23] . 71% of the patients treated for relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL) responded to the treatment either as complete response or complete response with incomplete hematologic recovery [24] . However, one patient experienced a fatal cytokine release syndrome [25] . data from the phase I/II study report that 4 out of 7 patients remained transfusion free for more than 90 days [17] . Lenti-D™ is another gene therapy for treatment of childhood cerebral adrenoleukodystrophy, a genetic disease causing progressive damage to the brain [18] . The cell therapeutic product Habeo™ is an injection of adipose-derived regenerative cells to treat hand involvement in systemic sclerosis [19] . Despite not reaching significance in the phase III trial, clinically meaningful improvements in hand function were achieved in a subgroup of patients with diffuse cutaneous scleroderma [20] . A managed access programme is currently being established to provide access for patients in advance of the full marketing authorisation [21] . Neocart® is an autologous chondrocyte-based tissue implant. In contrast to the promising phase I and II results, the primary efficacy endpoints were not met in the subsequent phase III clinical trials [22] . As the data are still being analysed, eventual consequences for the European market launch are currently unclear. ATIR101 is a cell based immunotherapeutic product containing T-lymphocyte enriched leukocytes. The product is intended to restore lymphocyte levels in patients undergoing stem cell transplantation from a partially matched (haploidentical) family donor. Conditional approval is expected for Q1 2019.
ATMPs with a planned launch in or after 2020
Two further CAR T-cell therapies currently in phase III clinical trial are planned for a centralized European market approval: JCAR017 (lisocabtagene maraleucel, liso-cel) is a treatment for aggressive B-cell nonHodgkin´s lymphoma. Data from the phase I study demonstrated an overall response rate of 66% with 50% of the patients achieving complete response at three months [23] . bb2121 is intended to treat multiple myeloma. Published efficacy data from the phase I trial report an overall treatment response of 95,5% [24] . Filing of a marketing authorisation application is anticipated for 2019 [25] . Tab-cel TM is an allogeneic T-cell immunotherapy to treat Epstein Barr Virus (EBV) associated post-transplant lymphoproliferative disorder and other EBV associated tumors [26] . The product was accepted into the EMA Priority Medicines regulatory pathway and is available to eligible patients through a multicentre expanded access protocol [27] . Evaluation of the expanded access programme demonstrates a response rate of 80% after hematopoietic stem cell transplantation and 83% after solid organ transplantation at a medium follow up of 3,3, months. Overall survival at 1 year among all patients treated was 90,3% [28] . Lenadogene nolparvovec (GS-010) is a gene therapy for treatment of Leber's hereditary optic neuropathy (LHON), a genetic disorder leading to a rapid loss of bilateral central vision [29] . REX-001 (Rexmylocel) are autologous bone marrow mononuclear cells administered through an intra-arterial catheter to treat critical limb ischemia [30, 31] . Multistem® is an off the shelf cell therapy product applicable for treatment of multiple distinct diseases. Multistem cells are currently in phase III clinical trials for treatment of ischaemic stroke and phase II for ulcerative colitis [32, 33] . Phase I studies for acute myocardial infarction and Graft vs. Host Disease have been completed [34, 35] .
PLX-PAD PLacental eXpanded cells are mesenchymallike stromal cells applicable without tissue or genetic matching. The cell-released cytokines, chemokines and growth factors are supposed to facilitate tissue regeneration [36] . PLX-PAD was granted FDA fast track approval and was accepted into the EMA Adaptive Regulatory Pathway [36] . Data of all ATMPs with a planned launch in or after 2020 are summarized in Table 4 . (Figure 2 ).
ATMPS in phase III or IV clinical trial
Apart from ATMPs following the centralized marketing authorisation pathway, 141 phase III and four phase IV clinical trials investigating potential ATMPs were identified. The majority (74%) of these are academic trials without an industrial sponsor. The remaining 26% are industry-driven research projects examining 31 different ATMP candidates. Indications are coronary artery disease, urinary stress incontinence, critical limb ischemia and chronic leg ulcers as well as cartilage restoration, oncological indications, mucopolysaccharidosis and spinal muscular atrophy. Most ATMP candidates in the industrial pipeline are cancer vaccines (29%), followed by gene (25%) and stem cell therapies (23%). Details are presented in Figure 3 . 13 studies are still active at the time of this report and have no results published. 3 studies with published results failed to demonstrate clinical efficacy in phase III. The marketing authorisation application of Cerepro® (Ark Therapeutics) was withdrawn for this reason [38] . Data on potential ATMPs in the industrial pipeline are summarized in Table 6 . The majority of clinical trials performed in an academic setting target stem cell transplantation for oncological indications (68%). Most of them are not embraced by the ATMP definition, as autologous stem cells for transplantation after chemotherapy are usually neither substantially manipulated nor intended to be used for a different essential function. Other indications are myocardial infarction and heart failure (9%), critical limb ischemia (6%), stroke, burns and infertility. Except for one tumor vaccine, all academic clinical trials investigate cell therapeutic products (Figure 4) . Details on ATMP candidates developed in academic settings are presented in Table 7 .
Conclusion
Advanced therapeutic medicinal therapies are still in their early days, but constantly evolving. Until 2017, more than 900 ATMPs have been examined in clinical trials worldwide [39] . Despite this impressive number of projects, the number of ATMPs on the market is still considerably low, and some of them were withdrawn only a couple of years after their market launch. Up to date, there are 8 ATMPs available via a centralized European marketing authorisation. Information on their commercial success is still very limited. GlaxoSmithKline, [41] . ATMPs that had been legally on the market before 2008 might avoid the complex authorisation procedure by evading under the Hospital exemption regulation. However, considering the actual survey result in combination with the 2012 data, these concerns have not been verified on a large scale.
6 new ATMPs shall be launched until 2020 and offer new treatment modalities for retinal dystrophy, ß-thalassemia, scleroderma, sickle-cell anaemia, adrenoleukodystrophy and leukaemia. Luxturna™, LentiGlobin™ and ATIR101 have already submitted a central marketing authorization application. For Luxturna™, the Committee for Medicinal products for Human Use has issued a positive opinion recommending approval [42] . LentiGlobin™ has been granted accelerated assessment by the EMA and ATIR101 expects conditional approval in 2019 [43, 44] .
Habeo™ and Neocart® did not reach significance in the primary efficacy endpoints in their respective phase III clinical trials, and eventual consequences for their marketing launch are unclear. For LentiD™, a modified paediatric investigation plan was accepted by the EMA in September 2018 [45] . 7 additional ATMPs currently in phase III clinical development are planned for a marketing authorisation application in or after 2020.
131 phase III clinical trials with ATMPs could be identified apart from the centralized marketing authorisation procedure. 31 ATMP candidates are industrial research projects with an assumptive interest in obtaining a marketing authorisation. However, reaching phase III stage does not guarantee a roadmap to successful clinical translation: Out of 19 finalized clinical trials, 26% were terminated prematurely and 23% of the ATMP candidates finally failed to demonstrate efficacy when evaluated against the current standard of care.
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